Additional file 2 of Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Figure S1 Location of the different CCND1 and EMSY probe sets in the genome. In addition the CCND1 and PAK1 probes used for PCR by Bostner are depicted. The UCSC Genome Browser was used to visualize the loci of interest in hg19 coordinates.Figure S2 A mixed effects regression of the log2-transformed reference sample estimates were modeled with reference probe-set, batch and their interaction as a fixed effect and sample as a random effect. Presented is a bar plot is of the variance in the batch estimates per probe-set. Figure S3 Data flow of patients entering the study, the reason of exclusion and finally analyzed for the specific markers.Figure S4 differences between Ki67 score on whole tissue slide and maximum score from 3 corresponding cores on TMA from tumors of a random series of 55 patients (comparable scores were available for 54 patients, since the staining on whole tissue slide failed for 1 tumor). Figure S5 Distribution of scores for mitosis markers: CCND1 probe set 1, CCND1 probe set 2, immunohistochemistry markers Ki67 and Cyclin D1, mitotic count per 2 mm2 and the square root transformed mitotic count per 2 mm2. Figure S6 Schoenfeld residuals for mitotic count (high (≥ 8 mitosis/2 mm2) versus low (< 8 mitosis/2 mm2)) over years in the entire cohort of 557 ER α positive patients for whom mitotic count could be assessed. Recurrence free interval survival was stratified by nodal status. (DOC 731 kb

Additional file 1 of Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Table S1: Distribution of clinico-pathological variables between patients with sufficient tumor material for biomarker analysis and the total group of patients who entered the study patients with sufficient tumor material. Table S2: Inter-observer variability for Ki67 and cyclin D1 immunohistochemistry scores antibody scoring system comparable cores. Table S3: Specifications of REMARK recommendations. Table S4: Multivariate Cox proportional hazard model of recurrence free interval (RFI) including mitotic count and treatment interaction, follow up truncated at 6 years. Table S5: Multivariate Cox proportional hazard model of recurrence free interval (RFI) including mitotic count and treatment interaction, follow up truncated at 6 years in HER2 negative patients. Table S6: Multivariate Cox proportional hazard model of recurrence free interval (RFI) including CCND1 copy number ratio and treatment interaction. Table S7a: Interaction tests between tamoxifen and EMSY probe sets analyzed as continuous. Table S7b: Interaction tests between tamoxifen and EMSY probe sets analyzed as binary factor. (PDF 368 kb

Additional file 2: of The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

I-SPY 2 Trial participating sites and institutional review boards (IRB). (XLSX 48 kb